Friday 23 October 2026 · Edition of the day

Current editionPast editions →

The Skeptic's Daily

The day's biggest stories, taken apart. For each one: what is actually established, what is only asserted, the questions worth asking — and a plausibility score for the central claim, given everything currently known.

Stories
2
Average plausibility
72%
How to read the score
It rates how well the core claim is evidenced — not how important the story is, nor whether it is good or bad news.
RegionAllGlobalAfricaNorth AmericaSouth AmericaAsia-PacificEuropeMiddle East
TopicAllPoliticsConflict & SecurityBusinessScienceHealth
01HealthAfrica

Officials link reported Nigerian Ebola patient's travel history to Uganda

The BBC says the patient traveled to Kampala, but the excerpt does not establish where infection occurred.

The BBC reported that officials described Nigeria's first Ebola patient as having vacationed in Uganda. The summary identifies her as the wife of a diplomat based in Abuja and says she traveled to Kampala.

What holds up

  • ✓The BBC attributes the patient's Uganda travel history to officials.
  • ✓The summary specifies Kampala as the vacation destination and Abuja as the diplomat's base.

What doesn't yet

  • ?The excerpt supplies no diagnostic results, travel dates or evidence identifying the place of infection.
  • ?The scope of 'first' is unspecified; the item does not clarify the outbreak or reporting period.

Ask before you share

  • →What laboratory evidence confirms the diagnosis?
  • →What period does 'first patient' refer to, and what does contact tracing establish?

Sources & original reporting

  1. [1]BBC News · Published 22 Oct 2026 · bbc.co.uk
02HealthAfrica

Researcher says Guinea-Bissau newborn vaccine trial will not proceed

The Guardian reports that the US-backed hepatitis B study was halted after drawing international criticism.

The Guardian reported that a hepatitis B vaccine trial involving newborns in Guinea-Bissau would not move forward, citing its lead researcher. The study was to be funded by the CDC and had drawn global backlash.

What holds up

  • ✓The excerpt names researcher Frederik Schaltz-Buchholzer as the source of the announcement.
  • ✓It identifies the proposed study's location, vaccine focus and intended CDC funding.

What doesn't yet

  • ?The announcement comes from a study participant; no separate funder or regulatory confirmation is supplied.
  • ?The excerpt does not explain the trial design, grounds for criticism or whether research elsewhere remains possible.

Ask before you share

  • →Have the funder and relevant authorities confirmed the halt?
  • →Does the decision end the study entirely or only its proposed work in Guinea-Bissau?

Sources & original reporting

  1. [1]The Guardian · Published 21 Oct 2026 · theguardian.com